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Background: Iridocorneal endothelial (ICE) syndrome occurs mainly in young and middle-aged women and
typically presents as a unilateral disease characterized by abnormalities of the iris and corneal endothelium. While
the ICE syndrome is known to be associated with glaucoma and bullous keratopathy, to our knowledge, only two
cases of ICE syndrome complicated with cystoid macular edema (CME) have been reported to date. In this paper,
we report a case of ICE syndrome complicated with CME treated at our institution.
Case presentation: The subject was a 51-year-old woman. In October 2013, she was examined by a primary care
physician for blurred vision in her left eye. Dyscoria and abnormality of the corneal endothelium were observed,
and the patient was diagnosed with ICE syndrome. In November of the same year, she was referred to our institution
with a decrease in visual acuity and CME, both in her left eye. At initial examination, her best corrected decimal visual
acuity was 1.0 (Snellen equivalent: 20/20) in the right eye and 0.5 (20/40) in the left eye. Intraocular pressure
was 12 mmHg in both eyes. She was diagnosed with Cogan–Reese syndrome based on marked ectropion
uveae, peripheral anterior synechia, and abnormalities of the corneal endothelium. Marked CME was observed
on ophthalmoscopy and optical coherence tomography. A topical non-steroidal anti-inflammatory drug
(nepafenac 0.1 %) was applied to the left eye four times daily from January 2014. Four weeks later, the CME
had resolved and her visual acuity was 1.0 (20/20).
Conclusion: While non-steroidal anti-inflammatory drugs and steroids did not appear to be effective in two
previously reported cases of ICE syndrome complicated with CME, topical nepafenac was effective in this case.
However, more such cases are needed before concluding that topical nepafenac is effective in this situation.
Keywords: Iridocorneal endothelial syndrome, Macular edema, Dyscoria, Abnormal corneal endothelium,
Non-steroidal anti-inflammatory drug, Topical nepafenac, Case report
Abbreviations: BCVA, Best corrected visual acuity; CME, Cystoid macular edema; ICE, Iridocorneal endothelial;
NSAID, Non-steroidal anti-inflammatory drug; OCT, Optical coherence tomographyBackground
Iridocorneal endothelial (ICE) syndrome, first reported
by Eagle and Yanoff in 1979 [1], is a disease character-
ized by abnormalities of the iris and the corneal endo-
thelium, and mainly occurs unilaterally in young and
middle-aged women. It is divided into the following
three subtypes based on examination findings for the iris
and cornea: progressive essential iris atrophy (corectopia,* Correspondence: masayuki@fujita-hu.ac.jp
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(http://creativecommons.org/publicdomain/zeiris atrophy or iris hole), Chandler syndrome (corneal
edema with mild to absent iris change), and Cogan–
Reese syndrome (nodular pigmented lesion of the iris).
On a pathological level, epithelialized abnormal corneal
endothelial cells migrate from the trabecular meshwork
into the iris plane [2], leading to angle-closure glau-
coma [3] and bullous keratopathy [4]. Although various
theories exist on the probable cause, such as viral infec-
tion, abnormal proliferation of neural crest cells, and
ectopic embryonic ocular surface epithelium, the actual
cause is yet to be ascertained. Only two reports havele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 a Photograph of the anterior segments of the left eye.
Corectopia with ectropion uveae and bridging at 4, 5, and 7 o’clock
and anterior synechia at 11 o’clock. b Optical coherence tomography
image of the anterior segments of the left eye. Anterior synechia
observed at 5 and 7 o’clock
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macular edema (CME) [5, 6], and an effective treatment
has not yet been reported. In this case, we treated the
patient with ICE syndrome complicated by CME with
topical nepafenac, a non-steroidal anti-inflammatory
drug (NSAID), and the findings are detailed here.
Case presentation
This case report adheres to the CARE guidelines and
methodology [7]. The subject was a 51-year-old woman
who presented with the chief complaint of blurred vision
in her left eye. Her medical and family history was unre-
markable. In October 2013, she consulted a primary care
physician for the blurred vision in her left eye. Her best
corrected decimal visual acuity (BCVA) was 1.0 (Snellen
equivalent: 20/20) in the right eye and 0.5 (20/40) in the
left eye. Intraocular pressure was 13 mmHg in both eyes.
Examination revealed dyscoria of the left eye, and specu-
lar microscopy showed an abnormality of the corneal
endothelium (dark area within endothelial cells), leading
to a diagnosis of ICE syndrome. In November of the
same year, the patient experienced a further decrease in
the visual acuity of her left eye and visited the physician
again. Her BCVA in the left eye was 0.4 (20/50). The
physician found CME using optical coherent tomog-
raphy (OCT); she was referred to our institution for de-
tailed examination and treatment.
Initial examination findings were as follows. BCVA
was 1.0 (20/20) in the right eye and 0.5 (20/40) in the
left eye. Intraocular pressure was 12 mmHg in the right
eye and 13 mmHg in the left eye. No abnormalities were
observed in the anterior segment or ocular media of the
right eye. In the left eye, corectopia with ectropion uveae
and bridging at 4, 5, and 7 o’clock and anterior synechia
at 11 o’clock were observed (Fig. 1a). OCT of the anter-
ior segment revealed ectropion uveae and bridging at 5
and 7 o’clock with adhesion between the iris and the
endothelial side of the cornea (Fig. 1b). Specular micros-
copy revealed an irregular rippled appearance of the
endothelium, reduced corneal endothelial cell density,
and a decreased percentage of hexagonal cells. These
findings were particularly pronounced in the inferior por-
tion where ectropion uveae and bridging were observed.
Fundus photography revealed CME in the left eye. Late-
phase petaloid pooling of fluorescence in the macular
region of the left eye was observed with fluorescein angi-
ography (Fig. 2). Macular edema was observed on OCT
(Fig. 3a). Her blood tests did not reveal any abnormal
results, and findings were negative for infections or auto-
immune diseases that could cause uveitis or CME.
The patient was diagnosed with ICE syndrome based on
the observation of marked ectropion uveae, peripheral an-
terior synechia, and abnormalities of the corneal endothe-
lium. The subtype was classified as Cogan–Reese syndromeowing to the absence of corneal edema and iris hole forma-
tion as well as ectropion uveae and corectopia.
The patient was treated with topical nepafenac 0.1 %
four times a day beginning in January 2014. The patient
was reexamined 4 weeks later, at which time the CME had
resolved and decimal BCVA was 1.0 (20/20). The patient
was followed up every month for the next 8 months and
BCVA was 1.0 (20/20) at each of these visits. Therefore,
nepafenac was discontinued in September 2014, after
8 months of use, and CME did not recur.
Conclusions
Although complications occur in patients who have
ICE syndrome with angle-closure glaucoma or bullous
Fig. 2 Fluorescein angiogram of the left eye. Hyperfluorescence is
observed in the macular region
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complication with CME.
The common causes of CME include retinal vascular dis-
eases, such as diabetic retinopathy, uveitis, post-intraocular
surgery for conditions such as cataract, macular diseasesFig. 3 a Optical coherence tomography image of the macula of the
left eye at the initial visit. Cystoid macular edema is observed. b Optical
coherence tomography image of the macula of the left eye after
4 months of topical nepafenac. Cystoid macular edema has resolvedsuch as vitreo-macular traction syndrome, retinitis pig-
mentosa, and use of eye drop formulations such as lata-
noprost [8, 9]. However, none of these CME-causing
conditions was observed in this case, leading us to con-
clude that CME had arisen as a complication of ICE
syndrome. Kocaoğlan et al. have discussed the prolifera-
tion of abnormal endothelial cells in the iridocorneal
angle and iris plane and the subsequent contraction of
the membrane of proliferated cells contributing to the
collapse of the inner blood-retinal barrier as a possible
mechanism for the complication of ICE syndrome with
CME [5]. In addition, Fourmaux & Velasque have spec-
ulated that the mechanism of action may be similar to
that in cases with CME after cataract surgery [6]. In
this case, we considered the following factors as a
mechanism for the onset of CME as a complication of
ICE syndrome. First, increasing use of swept-source op-
tical coherence tomography in recent years has led to
indications of a connection between the vitreous pocket
and Cloquet’s canal [10]. Further, in CME caused by
use of an eye drop formulation of latanoprost, a prosta-
glandin analog used for glaucoma [9] and CME follow-
ing cataract surgery [11], inflammatory material from
the anterior chamber may reach the macula and lead to
collapse of the inner blood-retinal barrier. Use of an
eye drop formulation of diclofenac sodium (an NSAID)
to prevent the development of CME after cataract sur-
gery has proven to be effective [11]. In this case, since
topical nepafenac was effective against macular edema,
we believe that prostaglandin-like material derived from
abnormal endothelial cells may have reached the mac-
ula and contributed to the collapse of the inner blood-
retinal barrier. A topical or systemic steroid is another
candidate for treatment of CME, but we used topical
nepafenac, because ICE syndrome often causes glau-
coma. Only one of the previous case reports docu-
mented the method of treatment [5], where both
steroid and NSAID eye drops appeared to be ineffect-
ive. It is difficult to account for this discrepancy. It is
possible that CME could have resolved in our patient as
part of the natural history of this disorder, but previous
cases did not include disappearance of CME, and we
had observed our patient for 3 months without treat-
ment and did not find improvement. Therefore, it is
more likely that topical nepafenac eliminated the macu-
lar edema. This case suggests the possibility that
NSAID eye drops could be effective for the treatment
of CME accompanying ICE syndrome. However, we
need more cases to confirm this possibility.
Finally, we need to address the issue of possible tox-
icity of NSAIDs to the cornea. Nepafenac-induced
corneal graft melt was reported in one case with graft-
versus-host disease [12], and nepafenac-associated
bilateral corneal melt was reported in one case where
Suzuki et al. BMC Ophthalmology  (2016) 16:155 Page 4 of 4nepafenac was used in error every 2 h [13]. Our pa-
tient and a previously reported patient treated with
nepafenac had no corneal complications, but in pa-
tients with ICE who have malfunctioning endothelial
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